Table. Patient and Treatment Characteristicsa.
| Characteristic | Allo-HCT (n = 76) | Consolidation therapy (n = 67) |
|---|---|---|
| Age, median (range), y | 50.5 (19.0-60.0) | 51.0 (24.0-60.0) |
| Age group, y | ||
| 18-40 | 16 (21) | 11 (16) |
| 41-60 | 60 (79) | 56 (84) |
| Sex | ||
| Female | 31 (41) | 31 (46) |
| Male | 45 (59) | 36 (54) |
| Cytogenetics | ||
| Normal karyotype | 54 (71) | 55 (82) |
| Other intermediate abnormalities | 16 (29) | 12 (18) |
| CEBPA status | ||
| Biallellic variant | 4 (5) | 1 (1) |
| NPM1 status/FLT3-ITD status | ||
| Variant/variant | 12 (17) | 13 (20) |
| Variant/wild type | 17 (25) | 14 (22) |
| Wild type/variant | 5 (7) | 3 (5) |
| Wild type/wild type | 35 (51) | 34 (53) |
| Missing | 7 (9) | 3 (4) |
| FLT3-ITD ratio, median (range) | 0.57 (0.36-1.00) | 0.54 (0.22-0.63) |
| ELN 2017 category | ||
| Favorable | 24 (32) | 19 (28) |
| Intermediate | 50 (66) | 46 (69) |
| Adverse | 2 (2) | 2 (3) |
| Available donor | ||
| Matched sibling | 18 (24) | 23 (34) |
| Matched unrelated (10/10) | 51 (67) | 35 (52) |
| 1 Allele mismatched unrelated (9/10) | 7 (9) | 9 (13) |
| CMV serostatus | ||
| Positive | 41 (54) | 36 (54) |
| Negative | 35 (46) | 31 (46) |
| Conditioning therapy | ||
| Intensive | 8 | NA |
| Reduced intensity | 61 | NA |
Abbreviations: allo-HCT, allogeneic hematopoietic cell transplant; CMV, cytomegalovirus; ELN, European Leukemia Network; ITD, internal tandem duplication; NA, not applicable.
a
Data are presented as number (percentage) of patients unless otherwise indicated.